Prometheus Biosciences (RXDX) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings or view top-rated stocks.

3 brokers have issued 1-year price targets for Prometheus Biosciences' stock. Their RXDX share price targets range from $200.00 to $200.00. On average, they predict the company's stock price to reach $200.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts.

Prometheus Biosciences, Inc. (NASDAQ:RXDX) issued its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative trailing twelve-month return on equity of 33.50%. The company's revenue for the quarter was down 71.8% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

Prometheus Biosciences (RXDX) raised $126 million in an initial public offering on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.